SCHEMBL2963546

SCHEMBL2963546

CCCCCCC(N)(C(=O)O)C(=O)OCc1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CETP P11597 3/20 0.48
ALDH1A1 P00352 4/20 0.47
CYP3A4 P08684 1/20 0.47
TSHR P16473 1/20 0.47
MAPK1 P28482 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
MBOAT4 Q96T53 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.44
HIF1A Q16665 1/20 0.44
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
SIRT2 Q8IXJ6 2/20 0.41
CTSL P07711 1/20 0.40
CTSS P25774 1/20 0.40
SIRT1 Q96EB6 1/20 0.40
HPGD P15428 1/20 0.40
GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8674203 1.00 CETP (0.48) CETPALDH1A1CYP3A4TSHRMAPK1
SCHEMBL149592 0.94 ALDH1A1 (0.49) CETPALDH1A1CYP3A4TSHRMAPK1
SCHEMBL28362146 0.89 ALDH1A1 (0.49) ALDH1A1CYP3A4TSHRMAPK1TDP1
SCHEMBL7440964 0.89 ALDH1A1 (0.49) ALDH1A1CYP3A4TSHRMAPK1TDP1
SCHEMBL28366123 0.89 ALDH1A1 (0.49) ALDH1A1CYP3A4TSHRMAPK1TDP1
SCHEMBL5711297 0.86 GRM2 (0.48) ALDH1A1MAPK1TDP1L3MBTL1SMN1; SMN2
SCHEMBL1167642 0.86 SMN1; SMN2 (0.46) ALDH1A1MAPK1TDP1L3MBTL1SMN1; SMN2
SCHEMBL1167641 0.86 SMN1; SMN2 (0.46) ALDH1A1MAPK1TDP1L3MBTL1SMN1; SMN2
SCHEMBL10855149 0.85 SMN1; SMN2 (0.47) ALDH1A1MAPK1TDP1L3MBTL1SMN1; SMN2
SCHEMBL7398999 0.85 ALDH1A1 (0.50) CETPALDH1A1CYP3A4TSHRMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7767811-B2 Kinetic resolutions of chiral 2- and 3-substituted carboxylic acids BRANDEIS UNIVERSITY (US) 2010-08-03 US disclosed
US-20060293536-A1 Kinetic resolutions of chiral 2- and 3-substituted carboxylic acids BRANDEIS UNIVERSITY (US) 2006-12-28 US disclosed
US-7057038-B2 Kinetic resolutions of chiral 2- and 3-substituted carboxylic acids BRANDEIS UNIVERSITY (US) 2006-06-06 US disclosed
EP-1419125-A4 KINETIC RESOLUTIONS OF CHIRAT 3- AND 3-SUBSTITUTED CARBOXYLIC ACIDS UNIV BRANDEIS (US) 2005-03-23 EP disclosed
US-20050020849-A1 Kinetic resolutions of chiral 2- and 3-substituted carboxylic acids DENG LI (US) 2005-01-27 US disclosed
US-6743914-B2 USING TERTIARY AMINE CATALYST BRANDEIS UNIVERSITY 2004-06-01 US disclosed
EP-1419125-A1 KINETIC RESOLUTIONS OF CHIRAT 3- AND 3-SUBSTITUTED CARBOXYLIC ACIDS Brandeis University (US) 2004-05-19 EP disclosed
EP-1305270-B1 KINETIC RESOLUTIONS OF CHIRAL 2- AND 3-SUBSTITUTED CARBOXYLIC ACIDS UNIV BRANDEIS (US) 2004-04-14 EP disclosed
US-20030166963-A1 Kinetic resolutions of chiral 2-and 3-substituted carboxylic acids NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2003-09-04 US disclosed
US-6562967-B2 Drug screening; purity BRANDEIS UNIVERSITY 2003-05-13 US disclosed
EP-1305270-A1 KINETIC RESOLUTIONS OF CHIRAL 2- AND 3-SUBSTITUTED CARBOXYLIC ACIDS Brandeis University (US) 2003-05-02 EP disclosed
WO-2003011799-A1 KINETIC RESOLUTIONS OF CHIRAT 3- AND 3-SUBSTITUTED CARBOXYLIC ACIDS BRANDEIS UNIVERSITY (US) 2003-02-13 WO disclosed
US-20020165393-A1 Kinetic resolutions of chiral 2- and 3-substituted carboxylic acids NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2002-11-07 US disclosed
US-20020151744-A1 Kinetic resolutions of chiral 2-and-3-substituted carboxylic acids NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2002-10-17 US disclosed
WO-2002010096-A1 KINETIC RESOLUTIONS OF CHIRAL 2- AND 3-SUBSTITUTED CARBOXYLIC ACIDS BRANDEIS UNIVERSITY (US) 2002-02-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020165393-A1 Kinetic resolutions of chiral 2- and 3-substituted carboxylic acids ADH5, ADH1C, TST CETP 1586/4885ALDH1A1 231/4885CYP3A4 320/4885
US-20050020849-A1 Kinetic resolutions of chiral 2- and 3-substituted carboxylic acids ADH5, ADH1C, TST CETP 1509/4885ALDH1A1 154/4885CYP3A4 309/4885
US-20060293536-A1 Kinetic resolutions of chiral 2- and 3-substituted carboxylic acids ADH5, ADH1C, TST CETP 1509/4885ALDH1A1 154/4885CYP3A4 309/4885
US-20030166963-A1 Kinetic resolutions of chiral 2-and 3-substituted carboxylic acids ADH5, ADH1C, TST CETP 1770/4885ALDH1A1 225/4885CYP3A4 350/4885
US-20020151744-A1 Kinetic resolutions of chiral 2-and-3-substituted carboxylic acids ADH5, ADH1C, TST CETP 1585/4885ALDH1A1 218/4885CYP3A4 290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.